MedTrace Logo

Overall and Disease Specific Survival in Patients With Confirmed MEN1 With or Without PNET (Pancreatic Neuroendocrine Tumors)

NCT03043508 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 45

Last updated 2019-05-23

No results posted yet for this study

Summary

OBJECTIVES:

The primary objective of this study is to evaluate the effect of estrogen on the development of the PNET in MEN1 patients.

The secondary objective is to evaluate the overall survival and disease specific survival in patients who have confirmed MEN1 with or without PNET and a pancreatic neuroendocrine tumor in relation to their hormone status. The secondary objective is to evaluate clinicopathologic features in relation to hormone status.

Conditions

  • Genetic Mutation
  • MEN1

Interventions

OTHER

Chart Review

Database reviewed to obtain patient and disease characteristics, laboratory values, imaging results, hormone parameters (menopausal status, bioidentical hormone use, oral contraception use, gestational status and diagnosis of a prolactinoma) and vital status.

BEHAVIORAL

Questionnaire

Participants sent an email questionnaire to complete regarding their pregnancy and hormone use history.

Sponsors & Collaborators

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Nancy D. Perrier, MD · M.D. Anderson Cancer Center

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-04-10
Primary Completion
2025-04-01
Completion
2026-04-01

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03043508 on ClinicalTrials.gov